Latest Breaking News On - ஆர்கோட் கூட்டாளர்கள் - Page 2 : comparemela.com

Search jobs AVEO Announces Appointment of Mike Ferraresso to Chief Commercial Officer BOSTON (BUSINESS WIRE) AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO’s commercial strategy and operations, including the commercialization of FOTIVDA ® (tivozanib). FOTIVDA is AVEO’s differentiated oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. “Directly on the heels of FOTIVDA’s approval, it is a pleasure to announce Mike’s appointment to chief commercial officer,” said Michael Bailey, president and chief executive officer of AVEO. “Mike’s hard work and dedication has played a crucial role in preparing for our evolution

United statesMichael baileyDavid pittsMike ferraressoMuro pharmaceuticalsPharma united kingdomDrug administrationPraecis pharmaceuticalsAssumption collegeExchange commissionEuropean unionPharmaceuticals incInfinity pharmaceuticalsKyowa kirinCritical therapeuticsAscent pediatrics